New Data at EULAR Signal Advances in RA, Myopathy, Gout
Barcelona has become the world capital of rheumatology by hosting the 2025 Annual Meeting of the European Alliance of Associations for Rheumatology (EULAR) in Spain.
'This is the world's largest rheumatology event,' said Daniel Aletaha, MD, president of EULAR and head of the Department of Rheumatology at the University Clinic for Internal Medicine III, MedUni Vienna, Vienna, Austria, during the conference opening session. He highlighted the scale of participation: 5125 abstracts submitted from 95 countries, 117 sessions, and 350 speakers from 45 nations.
Inflammatory and Autoimmune Disease
Among the plenary highlights was research led by Jason D. Turner, PhD, a postdoctoral research fellow at the University of Birmingham, Birmingham, England.
His comparative analysis of synovial tissue using single-cell and spatial transcriptomics identified overlapping disease pathways in spontaneous inflammatory arthritis and arthritis induced by immune checkpoint inhibitors.
'We found that the synovium in checkpoint inhibitor-associated arthritis is enriched with fibroblasts and T cells, is highly vascularised, and contains large numbers of CXCL9/10/11+ macrophages and CD8+ T cells. These findings support the current use of tumour necrosis factor inhibitors for this condition, although further investigation is needed to understand their applicability to spontaneous arthritis,' Turner explained.
Hector Chinoy, PhD, FRCP, professor of rheumatology at the University of Manchester and lead at the Salford Royal Adult Neuromuscular Service, Manchester, England, presented the results of the ALKIVIA phase 2 study.
This trial evaluated the efficacy of subcutaneous efgartigimod (PH20) administration in adults with active idiopathic inflammatory myopathy. The drug led to significant improvements in the Total Improvement Score compared with placebo and showed good tolerability and safety.
'These findings demonstrate the mechanistic importance of neonatal Fc receptor inhibition and suggest a potential pathogenic role for autoantibodies. These findings support the continued evaluation of the drug in the ongoing phase 3 trial' Chinoy said.
Scleroderma, Preclinical Rheumatoid Arthritis (RA), Gout, and Lupus
Adela‑Cristina Sarbu, MD, a researcher specialising in systemic sclerosis and interstitial lung disease at the University Hospital Bern, Bern, European Scleroderma Trials and Research group (EUSTAR), and the University of Zurich, Zurich, Switzerland, presented the findings from the EUSTAR cohort.
In conclusion, exposure to prostanoids appeared to be associated with a slower progression of interstitial lung disease in patients with mild vascular disease. In contrast, exposure to endothelin receptor antagonists appeared to be beneficial in preventing symptom worsening in patients with more severe vascular diseases.
'No independent mortality benefit was seen with vasoactive or vasodilator drugs. Their effectiveness seems to depend on the severity of vascular disease' Sarbu noted, calling for further long-term studies.
The ALTO study, an extension of the APIPPRA trial, led by Andrew Cope, PhD, of King's College London, London, England, found that a 1-year course of abatacept in individuals at high risk of developing RA could delay disease onset by up to 4 years.
'Individuals with baseline autoantibody profiles are more likely to develop the disease and respond well to T-cell co-stimulation blockade. Abatacept reduces the symptom burden during treatment but does not provide sustained benefits after treatment discontinuation. No new safety concerns were reported,' according to Cope.
Edoardo Cipolletta, MD, rheumatologist at the Marche University Hospital, Ancona, Italy, and research associate at the University of Nottingham, Nottingham, England, presented an analysis of data on primary care, hospitalization, and mortality outcomes related to gout, based on cohorts from the UK and Sweden.
The study found that achieving serum urate levels below 360 µmol/L within a year of initiating urate-lowering treatment was associated with a significantly lower risk for major adverse cardiovascular events.
The 5-year relative risk reduction ranged from 6% to 11%, with an absolute survival benefit of 1.3%-1.4%.
'The association was consistent regardless of prior cardiovascular disease and across all sensitivity analyses,' Cipolletta reported.
Richard A. Furie, MD, chief of Rheumatology at Northwell Health in New York, presented results from the REGENCY study, which evaluated obinutuzumab in patients with lupus nephritis.
Award Recognition
Miriam Ruiz Ponce, MSc, a predoctoral researcher at the Maimonides Biomedical Research Institute in Córdoba, Spain received one of the EULAR award for translational basic science.
She developed a mouse model of fatty liver disease associated with inflammatory arthritis to evaluate the anti-inflammatory and metabolic properties of apremilast, a drug commonly used in psoriatic arthritis.
'Early results have shown that the drug has promising effects, as it partially reverses liver damage, as well as inflammation. These are the initial results, but it could be a potential treatment for inflammation and for the deleterious effects on the liver in these patients. It is an honour to receive this award, which motivates us to continue our research under the leadership of my mentor, Nuria Barbarroja Puerto, PhD, the principal investigator of the potential treatment targeting inflammation and liver damage,' she said.
Chinoy disclosed financial relationships with AstraZeneca, Pfizer, PTC Therapeutics, and UCB. Furie disclosed the financial relationships with GSK and Genentech; the REGENCY study was funded by F. Hoffmann-La Roche. Sarbu and Cope disclosed having no relevant financial relationships. Turner, Cipolletta, and Ponce did not provide conflict-of-interest disclosures.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
an hour ago
- Medscape
Sclerosing Mesenteritis: Update on Rare GI Disease
The American Gastroenterological Association (AGA) has issued an updated pragmatic review on sclerosing mesenteritis (SM). Published in Clinical Gastroenterology and Hepatology, the update evaluates available evidence for diagnosis and treatment and examines opportunities for future research in SM, previously known by such names as misty mesentery, mesenteric panniculitis, and inflammatory pseudotumor. Led by Mark T. Worthington, MD, a professor of medicine in the Division of Gastroenterology and Hepatology at the University of Virginia in Charlottesville, Virginia, an expert AGA panel described SM as an uncommon benign idiopathic autoimmune disease of the mesenteric fat. Although of poorly understood etiology, gastroenterologists need to be prepared to diagnose it. 'CT radiologists increasingly are reporting SM and related lesions, such as misty mesentery,' Worthington told Medscape Medical News . 'We are also seeing new SM cases caused by immune checkpoint inhibitors in cancer treatment, and the oncologists ask us to manage this because it interferes with the treatment of the underlying malignancy. Those are often readily treated because we catch them so early.' Metabolic syndrome and associated conditions increase the risk for SM, as does aging. The recent changes are intended to help clinicians predict disease activity and the need for other testing or treatment. 'For instance, most cases are indolent and do not require aggressive treatment — often no treatment at all — but for those that are aggressive, we want the clinician to be able to identify those and make sure the treatment is appropriate. The aggressive cases may warrant tertiary referral,' Worthington said. 'A secondary cancer is a possibility in this condition, so drawing from the SM radiology studies, we try to help the clinician decide who needs other testing, such as PET-CT or biopsy, and who can be monitored.' As many as 60% of cases are asymptomatic, requiring no treatment. Abdominal pain is the most frequent symptom and its location on clinical examination should correspond to the SM lesion on imaging. Treatment involves anti-inflammatory medications tailored to disease severity and clinical response. No biopsy is not necessary if the lesion meets three of the five CT criteria reported by B. Coulier and has no features of more aggressive disease or malignancy. Although some have suggested that SM may be a paraneoplastic syndrome, current evidence does not support this. SM needs to be differentiated from other diagnoses such as non-Hodgkin's lymphoma, peritoneal carcinomatosis, and mesenteric fibromatosis. 'There are now CT guidelines for who actually has SM, who needs a biopsy or a PET-CT to rule-out malignancy, and who doesn't,' said Worthington. 'Radiologists do not always use the Coulier criteria for diagnosis, but often they will with encouragement. From this review, a GI clinician should be able to identify SM on CT.' Epidemiologically, retrospective CT studies have reported a frequency of 0.6%-1.1%, the panelists noted. And while demographic data are limited, a large early case series reported that SM patients had a mean age of 55 years and more likely to be men and of White race. Patients with SM do not have a higher prevalence of autoimmunity in general, but may have increased rates of metabolic syndrome, obesity, coronary artery disease, and urolithiasis, the panelists noted. The update allows room for differences in clinical judgment. 'For instance, a longer or more frequent CT surveillance interval can be justified depending on the patient's findings, and no one should feel locked in by these recommendations,' Worthington said. Medical Therapy Although there is no surgical cure, pharmacologic options are many. These include prednisone, tamoxifen, colchicine, azathioprine, thalidomide, cyclophosphamide, and methotrexate, as well as the biologics rituximab, infliximab and ustekinumab. Current corticosteroid-based therapies often require months to achieve a clinical response, however. Bowel obstruction is managed nonoperatively when feasible, but medically refractory disease may require surgical bypass. Offering his perspective on the guidance but not involved in its formulation, Gastroenterologist Stephen B. Hanauer, MD, a professor of medicine at Northwestern Medicine in Chicago, said, 'The most useful component of the practical review is the algorithm for diagnosis and determination when biopsy or follow-up imaging is reasonable in the absence of evidence.' He stressed that the recommendations are pragmatic rather than evidence-based 'as there are no controlled trials and the presentation is heterogeneous.' Hanauer added that none of the recommended treatments have been shown to impact reduction on imaging. 'Hence, all of the treatments are empiric without biological or imaging endpoints.' In his experience, patients with inflammatory features are the best candidates for immune-directed therapies as reduction in inflammatory markers is a potential endpoint, although no therapies have demonstrated an effect on imaging or progression. 'As an IBD doctor, I favor steroids and azathioprine or anti-TNF directed therapy, but again, there is no evidence beyond reports of symptomatic improvement.' Worthington and colleagues agreed that treatment protocols have developed empirically. 'Future investigation for symptomatic SM should focus on the nature of the inflammatory response, including causative cytokines and other proinflammatory mediators, the goal being targeted therapy with fewer side effects and a more rapid clinical response,' they wrote. Currently, said Worthington, the biggest gaps remain in treatment. 'Even the best studies are small and anecdotal, and we do not know the cytokine or other proinflammatory mediators.' In other comments, Gastroenterologist Eli D. Ehrenpreis, MD, research director, Internal Medicine Residency, at Advocate Lutheran General Hospital in Park Ridge, Illinois, and not involved in the update, found it fell short in several ways, including nomenclature. 'The appropriate term for this condition is mesenteric panniculitis, meaning inflammation of the mesenteric fat, seen histologically on biopsy. The term sclerosing mesenteritis introduces the idea of fibrosis, which is seen in a smaller number of patients, not all,' he told Medscape Medical News . Ehrenpreis also took issue with the inclusion of the cancer drug tamoxifen as the most common treatment used. 'Mesenteric panniculitis, when it does not represent a malignancy, is a benign disease,' he said. 'However, many patients on tamoxifen will experience hormone-related adverse effects such as breast tenderness and hot flashes.' He noted the drug has an FDA Black Box warning for uterine malignancies, pulmonary embolism, and other thromboembolic events, including stroke. Another significant gap, in his view, is the lack of recognition of the psychological effects on patients of the diagnosis. According to Ehrenpreis, more prospective analyses of treatments are needed with objective measures of success including symptom scoring and laboratory testing with erythrocyte sedimentation rate and C-reactive protein. 'And as with many rare diseases, a better understanding of the psychological effects of having a poorly understood disease and management of this challenge is vital to the comprehensive care of the patient with mesenteric panniculitis.' This guidance was supported by the AGA. Worthington reported renumeration from TriCity Surgery Center, Prescott, Ariz. The coauthor Wolf has received renumeration from AbbVie, Align Technology, Alnylam Pharmaceuticals, CVS Health ORP, Dexcom, Exact Sciences, HCA Healthcare, Johnson & Johnson, Eli Lilly, McKesson, Moderna, Regeneron Pharmaceuticals, Sarepta Therapeutics, Seagen, Stryker, and Thermo Fisher Scientific. Crockett has served as a consultant for IngenioRx. Pardi has served as a consultant for Boehringer Ingelheim and received research support from Atlantic, ExeGI Pharma, Rise Therapeutics, Janssen, Pfizer, Seres, Applied Molecular Transport, Takeda Pharmaceuticals, and Vedanta Biosciences. Hanauer and Ehrenpreis had no conflicts of interest relevant to their comments.
Medscape
2 hours ago
- Medscape
MRI Reveals Joint Damage After Cancer Treatment
TOPLINE: According to a UK study, whole-body MRI showed that patients with arthralgia who had previously received immune checkpoint inhibitor therapy had similar levels of inflammation and erosions as those with clinical arthritis, with distinct imaging patterns. METHODOLOGY: Researchers recruited 60 adults (mean age, 65 years; 43% women; 100% White) with new musculoskeletal symptoms during or within 6 months after receiving treatment with immune checkpoint inhibitors and 20 healthy control individuals (mean age, 62 years; 40% women; 100% White) from the UK, who underwent gadolinium contrast-enhanced whole-body MRI. A total of 35 patients had arthralgia and 25 had inflammatory arthritis. Two independent masked assessors graded joint, tendon, bursal, entheseal, and whole spinal imaging lesions, with consensus reporting and a 6-month follow-up. TAKEAWAY: Distinct global inflammatory patterns were identified on the MRI scans: polymyalgia rheumatica (extracapsular; 12%), peripheral inflammatory arthritis (37%), spondyloarthropathy (n = 1), and a non-specific pattern (20%). Median total appendicular joint synovitis, joint erosion, enthesitis, and tenosynovitis scores were significantly higher in both arthralgia and inflammatory arthritis groups than in control individuals, with no significant differences found between the arthralgia and inflammatory arthritis subgroups. Among the patients exposed to immune checkpoint inhibitors, acromioclavicular (77%), glenohumeral (75%), wrist (73%), and metacarpophalangeal (59%) joints were most frequently affected by synovitis. Patients with a peripheral inflammatory arthritis pattern were most likely to require disease-modifying antirheumatic drug therapy, showing the highest initial and ongoing glucocorticoid requirement. IN PRACTICE: "[The study] results suggest that the overall burden of musculoskeletal toxicity associated with immune checkpoint inhibitors is currently under-recognised and highlights the range and extent of inflammation in all patients presenting with new musculoskeletal symptoms after exposure to an immune checkpoint inhibitor. Rheumatology assessment should be considered by oncologists for patients who develop arthralgia alone," the authors wrote. SOURCE: This study was led by Kate Harnden, MBChB, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, England. It was published online on June 10, 2025, in The Lancet Rheumatology. LIMITATIONS: Feet and ankles were not imaged during the study due to logistical constraints. The 6-month follow-up period was relatively short for determining long-term musculoskeletal outcomes. Some patients were classified as having non-specific inflammation patterns, whose significance was unclear. A few participants had preexisting autoimmune diseases, possibly increasing their baseline risk for arthritis. Additionally, intra-assessor agreement was not measured. DISCLOSURES: This study received support from the National Institute for Health and Care Research Leeds Biomedical Research Centre. One author reported receiving a EULAR bursary travel award, and some authors reported having financial ties with various sources. Details are provided in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
2 hours ago
- Medscape
Sepsis Diagnosis Delays Pose Urgent Safety Risk: HSSIB
The Health Services Safety Investigations Body (HSSIB) has warned that delays in diagnosing sepsis continue to pose an 'urgent and persistent safety risk' to NHS patients in England. In a new report, the independent body examined three cases where patients faced severe harm or death due to missed or late sepsis diagnoses. The findings highlight continued challenges faced by clinicians in identifying sepsis early. The UK Sepsis Trust told The Guardian that learning from such cases could help prevent up to 10,000 deaths each. Sepsis is associated with around 48,000 deaths and affects approximately 245,000 people each year in the UK. Key Issues Identified in Sepsis Care The HSSIB identified 10 areas for improvement. While based on the three cases reviewed, the recommendations may apply more broadly across the NHS. 'These reports show a consistent pattern of issues around the early recognition and treatment of sepsis,' said Melanie Ottewill, senior safety investigator at the HSSIB. Key areas for improvement included: Poor coordination of care, including inconsistent referral pathways, variation in clinical expertise, and access to medication. Weak communication between medical staff and across organisations. Failure to recognise early signs such as new-onset confusion or suspected infection. Case Studies Highlight Diagnostic Challenges The three HSSIB's investigations involved patients with a urinary tract infection, abdominal pain, and a diabetic foot infection. Two of the patients died. The third required an amputation and faced a long recovery. The report emphasised that sepsis symptoms can vary widely, with no single diagnostic tool reliably identifying the condition. Factors such as age, pre-existing health conditions, and immune function can alter how sepsis presents. In two of the three cases, new confusion — a known red flag — was not recognised. In one case, the patient's family told investigators they had raised concerns but felt they were not listened to. Barriers to Timely Treatment Each investigation uncovered different breakdowns in the system. One case showed that a lack of consistent referral processes and limited information sharing between hospitals contributed to delayed diagnosis. Another case identified the absence of a direct route of escalation from nursing staff to senior doctors for deteriorating patients. It also found that nurses were hesitant to begin a sepsis screen without confirmed signs of infection, which delayed escalation to senior clinicians. In the third case, a delay in prescribing by an out-of-hours GP using the electronic patient record system meant that a patient waited nearly 20 hours to receive antibiotics. 'These reports provide a valuable reiteration of how quickly sepsis can develop – and therefore how swift diagnosis and treatment must be,' said Dr Ron Daniels, founder and chief medical officer of the UK Sepsis Trust. 'We need a commitment from health ministers on the development and implementation of a 'sepsis pathway' – a standardised treatment plan that ensures patients receive the right care from the point at which they present their symptoms to a clinician through to receiving their diagnosis.' Ottewill added: 'The findings also highlight the imperative of listening to families when they express concerns about their loved one and tell us about changes in how they are.'
